Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study

English version České info

Background:
Intrapartum and neonatal single-dose nevirapine (NVP) reduces the risk of mother-to-child HIV transmission but also induces viral resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs. This drug resistance largely fades over time. We hypothesized that women with a prior single-dose NVP exposure would have no more than a 10% higher cumulative prevalence of failure of their NNRTI-containing antiretroviral therapy (ART) over the first 48 wk of therapy than would women without a prior exposure.

Methods and Findings:
We enrolled 355 NVP-exposed and 523 NVP-unexposed women at two sites in Zambia, one site in Kenya, and two sites in Thailand into a prospective, non-inferiority cohort study and followed them for 48 wk on ART. Those who died, discontinued NNRTI-containing ART, or had a plasma viral load ≥400 copies/ml at either the 24 wk or 48 wk study visits and confirmed on repeat testing were characterized as having failed therapy. Overall, 114 of 355 NVP-exposed women (32.1%) and 132 of 523 NVP-unexposed women (25.2%) met criteria for treatment failure. The difference in failure rates between the exposure groups was 6.9% (95% confidence interval [CI] 0.8%–13.0%). The failure rates of women stratified by our predefined exposure interval categories were as follows: 47 of 116 women in whom less than 6 mo elapsed between exposure and starting ART failed therapy (40%; p<0.001 compared to unexposed women); 25 of 67 women in whom 7–12 mo elapsed between exposure and starting ART failed therapy (37%; p = 0.04 compared to unexposed women); and 42 of 172 women in whom more than 12 mo elapsed between exposure and starting ART failed therapy (24%; p = 0.82 compared to unexposed women). Locally weighted regression analysis also indicated a clear inverse relationship between virologic failure and the exposure interval.

Conclusions:
Prior exposure to single-dose NVP was associated with an increased risk of treatment failure; however, this risk seems largely confined to women with a more recent exposure. Women requiring ART within 12 mo of NVP exposure should not be prescribed an NNRTI-containing regimen as first-line therapy.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study. PLoS Med 7(2): e32767. doi:10.1371/journal.pmed.1000233
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000233

Souhrn

Zdroje

1. World Health Organization The 3 by 5 initiative: AIDS in children. Available: http://www.who.int/3by5/paediatric/en/index.html. Accessed 7 February 2007

2. De CockKM

FowlerMG

MercierE

de VincenziI

SabaJ

2000 Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283 1175 1182

3. GuayLA

MusokeP

FlemingT

BagendaD

AllenM

1999 Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354 795 802

4. JacksonJB

MusokeP

FlemingT

GuayLA

BagendaD

2003 Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362 859 868

5. LallemantM

JourdainG

Le CoeurS

MaryJY

Ngo-Giang-HuongN

2004 Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351 217 228

6. DabisF

BequentL

EkoueviDK

VihoI

RouentF

2005 Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19 309 318

7. StringerEM

SinkalaM

StringerJS

MzyeceE

MakukaI

2003 Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 17 1377 1382

8. PerezF

MukotekwaT

MillerA

Orne-GliemannJ

GlenshawM

2004 Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. Trop Med Int Health 9 774 783

9. Perez-ThenE

PenaR

Tavarez-RojasM

PenaC

QuinonezS

2003 Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience. J Acquir Immune Defic Syndr 34 506 511

10. SpensleyA

SripipatanaT

TurnerAN

HoblitzelleC

RobinsonJ

2008 Preventing Mother-to-Child Transmission of HIV in Resource-Limited Settings: The Elizabeth Glaser Pediatric AIDS Foundation Experience. Am J Public Health 99 631 637

11. McConnellMS

StringerJS

KourtisAP

WeidlePJ

EshlemanSH

2007 Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? Am J Obstet Gynecol 197 3 Suppl S56 63

12. ArrivéE

NewellML

EkoueviDK

ChaixML

ThiebautR

2007 Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 36 1009 1021

13. EshlemanSH

GuayLA

WangJ

MwathaA

BrownER

2005 Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 40 24 29

14. LoubserS

BalfeP

ShermanG

HammerS

KuhnL

2006 Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20 995 1002

15. FlysT

NissleyDV

ClaasenCW

JonesD

ShiC

2005 Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 192 24 29

16. JourdainG

Ngo-Giang-HuongN

Le CoeurS

BowonwatanuwongC

KantipongP

2004 Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351 229 240

17. LockmanS

ShapiroRL

SmeatonLM

WesterC

ThiorI

2007 Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356 135 47

18. World Health Organization 2004 Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. Geneva. Available: http://www.who.int/hiv/pub/prev_care/en/. Accessed 1 July 2009

19. World Health Organization 2006 Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. Geneva: WHO. Available: http://www.who.int/hiv/pub/guidelines/en/. Accessed 1 July 2009

20. PiaggioG

ElbourneDR

AltmanDG

PocockSJ

EvansSJW

2006 Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement. JAMA 295 1152 1160

21. AltmanDG

1991 Practical Statistics for Medical Research. Boca Raton (Florida) Chapman and Hall/CRC

22. ClevelandWS

DevlinSJ

1988 Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc 83 596 610

23. LallemantM

2005 July 24–27 Response to the therapy after prior exposure to nevirapine; 3rd IAS Conference on HIV Pathogenesis and Treatment. TuFo 0205

24. ZijenahLS

KadzirangeG

RusankanikoS

KufaT

GonahN

2006 A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short-course zidovudine and their spouses in Chitungqiza, Zimbabwe. Cent Afr J Med 52 1 8

25. CoffiePA

EkoueviDK

ChaixML

Tonwe-GoldB

ClarisseAB

2008 Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 46 611 621

26. ChiBH

SinkalaM

StringerEM

CantrellRA

MtongaV

2006 Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 21 957 964

27. KuhnL

SemrauK

RamachandranS

SinkalaM

ScottN

2009 Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr 52 132 136

28. CoovadiaA

HuntG

AbramsEJ

ShermanG

MeyersT

2009 Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infec Dis 48 462 72

29. World Health Organization 2006 Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access. Geneva: WHO. Available: http://www.who.int/hiv/pub/mtct/en/. Accessed 1 July 2009

30. ChiB

SinkalaM

MbeweF

CantrellRA

KruseG

2007 Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370 1698 1705

31. FarberC

2006 March 1 Out of Control: AIDS and the Corruption of Medical Science. Harper's Magazine

32. CampaAM

Shor-PosnerG

BaumMK

1999 HIVNET nevirapine trials. Lancet 354 1816

33. BeckermanKP

2003 Long-term findings of HIVNET 012: the next steps. Lancet 362 842 843

34. Lockman S and A5208/OCTANE Study Team 2009 Lopinavir/ritonavir+Tenofovir/Emtricitabine Is Superior to Nevirapine+Tenofovir/Emtricitabine for Women with prior Exposure to Single-dose Nevirapine: A5208 (“OCTANE”). 16th Conference on Retroviruses and Opportunistic Infections (94LB). Available at http://www.retroconference.org/2009/Abstracts/36738.htm. Accessed 21 January 2010

35. World Health Organization, UNICEF, UNAIDS 2008 Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008. Available: http://www.who.int/hiv/pub/2009progressreport/en/. Accessed 21 January 2010